- Amneal Pharmaceuticals ( NYSE: AMRX ) has submitted a New Drug Application to the US FDA for IPX203 , carbidopa/levodopa (CD/LD) extended-release capsules for Parkinson’s disease.
- The application is based on phase 3 data that showed more "good on" time compared to immediate-release CD/LD, even when IPX203 was dosed on average three times per day and immediate-release CD/LD was dosed on average five times.
- Results also showed that those on IPX203 has significantly less "off" time compared to immediate-release CD/LD.
- Seeking Alpha's Quant Rating views Amneal ( AMRX ) as a hold with high marks for valuation and profitability .
For further details see:
Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment